Doreen A. Ezeife

577 total citations
25 papers, 353 citations indexed

About

Doreen A. Ezeife is a scholar working on Economics and Econometrics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Doreen A. Ezeife has authored 25 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Economics and Econometrics, 11 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Doreen A. Ezeife's work include Economic and Financial Impacts of Cancer (13 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Lung Cancer Treatments and Mutations (9 papers). Doreen A. Ezeife is often cited by papers focused on Economic and Financial Impacts of Cancer (13 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Lung Cancer Treatments and Mutations (9 papers). Doreen A. Ezeife collaborates with scholars based in Canada, United States and Netherlands. Doreen A. Ezeife's co-authors include Natasha B. Leighl, Bishal Gyawali, Lisa W. Le, Kelvin Chan, Jennifer Law, Frances A. Shepherd, Tony H. Truong, Nancy Nixon, Adrian G. Sacher and Matthew C. Cheung and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Doreen A. Ezeife

23 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Doreen A. Ezeife Canada 11 163 132 104 64 40 25 353
Wei Fang Dai Canada 8 102 0.6× 162 1.2× 62 0.6× 57 0.9× 18 0.5× 21 260
Koen Degeling Australia 10 104 0.6× 125 0.9× 65 0.6× 79 1.2× 16 0.4× 35 310
Mathias Lidgren Sweden 7 209 1.3× 241 1.8× 44 0.4× 123 1.9× 29 0.7× 12 442
Demetrios Simos Canada 11 53 0.3× 178 1.3× 58 0.6× 138 2.2× 42 1.1× 25 337
Elisabeth M. Wever Netherlands 9 63 0.4× 220 1.7× 400 3.8× 64 1.0× 20 0.5× 11 536
Max Parmar United Kingdom 9 35 0.2× 165 1.3× 180 1.7× 63 1.0× 13 0.3× 22 354
Martine Bomb United Kingdom 6 55 0.3× 226 1.7× 65 0.6× 31 0.5× 21 0.5× 11 380
Victoria Kaestner United States 6 46 0.3× 156 1.2× 58 0.6× 49 0.8× 10 0.3× 7 308
Giovanni Zanotti United States 11 45 0.3× 142 1.1× 215 2.1× 97 1.5× 84 2.1× 36 349
Emmanuelle Kempf France 12 59 0.4× 206 1.6× 200 1.9× 91 1.4× 30 0.8× 56 536

Countries citing papers authored by Doreen A. Ezeife

Since Specialization
Citations

This map shows the geographic impact of Doreen A. Ezeife's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doreen A. Ezeife with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doreen A. Ezeife more than expected).

Fields of papers citing papers by Doreen A. Ezeife

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doreen A. Ezeife. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doreen A. Ezeife. The network helps show where Doreen A. Ezeife may publish in the future.

Co-authorship network of co-authors of Doreen A. Ezeife

This figure shows the co-authorship network connecting the top 25 collaborators of Doreen A. Ezeife. A scholar is included among the top collaborators of Doreen A. Ezeife based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doreen A. Ezeife. Doreen A. Ezeife is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ruan, Yibing, Emily Heer, Matthew T. Warkentin, et al.. (2023). The association between neighborhood‐level income and cancer stage at diagnosis and survival in Alberta. Cancer. 130(4). 563–575. 3 indexed citations
2.
Karim, Safiya, et al.. (2023). Impact of Oncology Drug Review Times on Public Funding Recommendations. Current Oncology. 30(8). 7706–7712. 2 indexed citations
3.
Ezeife, Doreen A., et al.. (2023). Un accès équitable aux soins contre le cancer pour les personnes noires au Canada. Canadian Medical Association Journal. 195(1). E51–E55.
4.
Ezeife, Doreen A., Eldon Spackman, Rosalyn A. Juergens, et al.. (2022). The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 14. 27 indexed citations
5.
Ezeife, Doreen A., et al.. (2022). Ensuring equitable access to cancer care for Black patients in Canada. Canadian Medical Association Journal. 194(41). E1416–E1419. 10 indexed citations
6.
Makarem, Maisam, Doreen A. Ezeife, Adam C. Smith, et al.. (2021). Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer—A Cost-Efficient Strategy in a Public Healthcare System. Current Oncology. 28(5). 3268–3279. 11 indexed citations
7.
Ezeife, Doreen A., Eldon Spackman, Rosalyn A. Juergens, et al.. (2021). OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(10). S876–S876. 3 indexed citations
8.
Ezeife, Doreen A., Steven Yip, Jennifer Law, et al.. (2021). The financial impact of cancer care on renal cancer patients.. PubMed. 28(4). 10762–10767. 2 indexed citations
9.
Rydz, Natalia, et al.. (2021). Paraneoplastic acquired haemophilia A in extensive-stage small cell lung cancer (ES-SCLC) in the era of immunotherapy. BMJ Case Reports. 14(1). e236973–e236973. 2 indexed citations
10.
Laurie, Scott A., Jason Agulnik, Desirée Hao, et al.. (2020). 1195P The value of detecting resistance through liquid biopsy. Annals of Oncology. 31. S786–S787. 1 indexed citations
11.
Ezeife, Doreen A., François Dionne, Aline Fusco Fares, et al.. (2019). Value assessment of oncology drugs using a weighted criterion‐based approach. Cancer. 126(7). 1530–1540. 10 indexed citations
12.
Cheng, Sierra, et al.. (2019). Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?. Journal of the National Comprehensive Cancer Network. 17(12). 1489–1496. 3 indexed citations
13.
Ezeife, Doreen A., Derek S. Chew, Nancy Nixon, et al.. (2018). Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. Lung Cancer. 125. 1–7. 26 indexed citations
14.
Ezeife, Doreen A., Barbara Melosky, Sophia Lin, et al.. (2018). Afatinib in Advanced Pretreated Non-Small-Cell Lung Cancer—A Canadian Experience. Current Oncology. 25(5). 385–390. 3 indexed citations
15.
Ezeife, Doreen A., Sally C. M. Lau, Jennifer Law, et al.. (2018). Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. Clinical Lung Cancer. 20(4). 231–236. 43 indexed citations
16.
Ezeife, Doreen A., Joshua C. Morganstein, Sally C. M. Lau, et al.. (2018). Financial toxicity among patients with lung cancer in a publicly funded health care system.. Journal of Clinical Oncology. 36(30_suppl). 192–192. 1 indexed citations
17.
Cheng, Sierra, Matthew C. Cheung, Di Jiang, et al.. (2017). Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?. Journal of Clinical Oncology. 35(24). 2764–2771. 42 indexed citations
18.
Nixon, Nancy, Omar Khan, Patricia A. Tang, et al.. (2017). Drug development for breast, colorectal, and non–small cell lung cancers from 1979 to 2014. Cancer. 123(23). 4672–4679. 17 indexed citations
19.
Ezeife, Doreen A., Sunil Parimi, Tony H. Truong, et al.. (2017). The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value. Journal of the National Comprehensive Cancer Network. 15(8). 1005–1013.
20.
Ezeife, Doreen A., et al.. (2015). Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration. Cancer. 121(10). 1688–1693. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wei Fang Dai Breakdown of academic impact, for papers by Koen Degeling Breakdown of academic impact, for papers by Mathias Lidgren Breakdown of academic impact, for papers by Demetrios Simos Breakdown of academic impact, for papers by Elisabeth M. Wever Breakdown of academic impact, for papers by Max Parmar Breakdown of academic impact, for papers by Martine Bomb Breakdown of academic impact, for papers by Victoria Kaestner Breakdown of academic impact, for papers by Giovanni Zanotti Breakdown of academic impact, for papers by Emmanuelle Kempf
Rankless by CCL
2026